Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-09-25FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. to update its labeling.
-
FDA approval · 2013-09-25FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc. This supplemental approval updates the existing NDA, typi…
-
FDA approval · 2013-09-25FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in an update to its labeling.
-
CLINICAL_TRIALS trial_result · 2013-09-17Clinical Trial Update: Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method [Phase 2]
A Phase 2 double-blind bridging study of L059 (levetiracetam) in patients with epilepsy has completed, reporting results from the Phase 2 tr…
-
CLINICAL_TRIALS research · 2013-09-16Clinical Trial Update: Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
A systematic review evaluating retigabine as adjunctive therapy in partial epilepsy, summarizing available trial evidence on efficacy and sa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-09-13FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc., under NDA021505, to update the product labeli…
-
FDA approval · 2013-09-06FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: Determining the Extent of Diffusion Tensor Abnormalities in Focal Cortical Dysplasia
The trial has completed an assessment of diffusion tensor imaging abnormalities in focal cortical dysplasia, in the context of epilepsy.
-
CLINICAL_TRIALS trial_result · 2013-08-28Clinical Trial Update: RNS® System Pivotal Study [Phase 3]
NeuroPace's RNS System completed a pivotal Phase 3 trial for epilepsy. Results from the study were posted in 2013.
-
FDA approval · 2013-08-23FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, updating the product labeling.
-
FDA approval · 2013-08-22FDA Approved: FOSPHENYTOIN — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Fosphenytoin Sodium (Fosphenytoin) by Fresenius Kabi USA, LLC.
-
FDA approval · 2013-08-16FDA Approved: TROKENDI XR — Original Application (Supernus Pharmaceuticals, Inc.)
FDA approved TROKENDI XR (topiramate extended-release) in an Original Application by Supernus Pharmaceuticals, expanding the topiramate port…
-
CLINICAL_TRIALS trial_result · 2013-08-16Clinical Trial Update: Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy [Phase 3]
Phase 3 trial of polyunsaturated fatty acids as adjunctive treatment for refractory epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2013-08-16Clinical Trial Update: An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy
An observational study evaluating the long-term retention rate of topiramate in participants with epilepsy; the study is completed and resul…
-
CLINICAL_TRIALS trial_result · 2013-08-09Clinical Trial Update: Dexmedetomidine in Seizure Patients [Phase 1]
This Phase 1 trial at UCSF evaluated dexmedetomidine in patients with epilepsy and has completed, focusing on safety and pharmacokinetics.
-
FDA approval · 2013-08-08FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2013-08-08Clinical Trial Update: Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
A completed clinical trial assessed lacosamide (VIMPAT) as adjunctive therapy for adults with partial-onset seizures; results were posted in…
-
FDA approval · 2013-08-07FDA Approved: LEVETIRACETAM — Supplemental Application (WG Critical Care, LLC)
The FDA approved a supplemental application for levetiracetam submitted by WG Critical Care, LLC.
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) [Phase 2, Phase 3]
This clinical trial update reports results from a combined treatment with praziquantel and albendazole for neurocysticercosis and related ep…
-
FDA approval · 2013-08-06FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN (extended phenytoin sodium) submitted by Viatris Specialty LLC.
-
FDA approval · 2013-08-05FDA Approved: CERETEC — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approves a supplemental application for CERETEC (TECHNETIUM TC-99M EXAMETAZIME) from Medi-Physics Inc. dba GE Healthcare.
-
CLINICAL_TRIALS trial_result · 2013-08-01Clinical Trial Update: Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy [Phase 4]
A Phase 4 clinical trial evaluated methylphenidate for treating attention-deficit/hyperactivity disorder in children with coexisting epileps…
-
FDA approval · 2013-07-31FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote ER (divalproex sodium) from AbbVie Inc. This action represents an approved supplement t…
-
FDA approval · 2013-07-29FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) by Novartis Pharmaceuticals Corporation, typically resulting in upda…
-
FDA approval · 2013-07-26FDA Approved: CLONAZEPAM — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for clonazepam filed by Par Health USA, LLC.